Expression of Concern: Potential Risk for Developing Severe COVID-19 Disease Among Anabolic Steroid Users

February 2021 in “ BMJ case reports ”

Flavio Cadegiani, Erica Lin, Andy Goren, Carlos Gustavo Wambier

anabolic steroid oxandrolone proxalutamide antiandrogen

TLDR Anabolic steroid users may face higher risk of severe COVID-19.

A 28-year-old man who had been using the anabolic steroid oxandrolone developed severe COVID-19 symptoms, which rapidly worsened over 4 days. After receiving a single 600 mg dose of the novel antiandrogen proxalutamide, his symptoms and disease severity markers significantly improved within 24 hours. This case suggested a potential link between anabolic steroid use and increased COVID-19 severity.

View this study on casereports.bmj.com →

Discuss this study in the Community →

Research cited in this study

11 / 11 results

Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

research Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial

41 citations, February 2021 in “Cureus”

Dutasteride treatment in men with mild to moderate COVID-19 reduced viral shedding, inflammation, and recovery time without serious side effects.

research Enzalutamide, a Prostate Cancer Therapeutic, Downregulates TMPRSS2 in Lung and Reduces Cellular Entry of SARS-CoV-2

1 citations, January 2021 in “Research Square (Research Square)”

Enzalutamide, a prostate cancer drug, may help prevent COVID-19 by blocking the virus from entering lung cells.

research Anti-Androgens May Protect Against Severe COVID-19 Outcomes: Results From a Prospective Cohort Study of 77 Hospitalized Men

49 citations, January 2021 in “Journal of The European Academy of Dermatology and Venereology”

Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.

research Androgen Signaling Regulates SARS-CoV-2 Receptor Levels and Is Associated with Severe COVID-19 Symptoms in Men

139 citations, December 2020 in “Cell Stem Cell”

Male hormones affect COVID-19 severity and certain drugs targeting these hormones could help reduce the risk.

research 5-Alpha-Reductase Inhibitors Are Associated With Reduced Frequency of COVID-19 Symptoms in Males With Androgenetic Alopecia

36 citations, November 2020 in “Journal of The European Academy of Dermatology and Venereology”

5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.

research Clinical Symptoms of Hyperandrogenic Women Diagnosed with COVID-19

29 citations, October 2020 in “Journal of the European Academy of Dermatology and Venereology”

Women with high androgen levels may have more severe COVID-19 symptoms.

Male Balding as a Major Risk Factor for Severe COVID-19: A Possible Role for Targeting Androgens and Transmembrane Protease Serine 2 to Protect Vulnerable Individuals

research Male Balding as a Major Risk Factor for Severe COVID-19: A Possible Role for Targeting Androgens and Transmembrane Protease Serine 2 to Protect Vulnerable Individuals

6 citations, September 2020 in “Journal of The American Academy of Dermatology”

Severe male balding may increase the risk of serious COVID-19, and treatments that reduce androgens or block a specific enzyme might help protect these individuals.

Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign

research Androgenetic Alopecia in COVID-19: Comparison to Age-Matched Epidemiologic Studies and Hospital Outcomes With or Without the Gabrin Sign

32 citations, July 2020 in “Journal of The American Academy of Dermatology”

AGA linked to worse COVID-19 outcomes in men.

research Androgenetic Alopecia Present in the Majority of Patients Hospitalized with COVID-19: The 'Gabrin Sign'

119 citations, May 2020 in “Journal of The American Academy of Dermatology”

Most COVID-19 patients in hospitals have androgenetic alopecia, more in men, suggesting a link between androgen sensitivity and severe COVID-19 symptoms.

research Androgen Sensitivity Gateway to COVID-19 Disease Severity

123 citations, May 2020 in “Drug Development Research”

Men's sensitivity to male hormones might affect how severe COVID-19 gets for them.

research Emerging Medication for the Treatment of Male Hypogonadism

77 citations, May 2012 in “Expert Opinion on Emerging Drugs”

New treatments for male hypogonadism are effective and should be personalized.

Similar Research

5 / 756 results

research Letter to the Editor on COVID-19 Infection in Men on Testosterone Replacement Therapy

1 citations, March 2021 in “The Journal of Sexual Medicine”

The letter suggests testosterone replacement therapy might worsen COVID-19 outcomes.

research Androgen Receptor Modulators: A Review of Recent Patents and Reports (2012-2018)

23 citations, May 2019 in “Expert Opinion on Therapeutic Patents”

New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.

research Novel Uses for the Anabolic Androgenic Steroids Nandrolone and Oxandrolone in the Management of Male Health

15 citations, August 2016 in “Current Urology Reports”

Nandrolone and oxandrolone could help treat male health issues like muscle loss and low testosterone.

research Adverse Health Effects of Androgen Use

25 citations, June 2017 in “Molecular and Cellular Endocrinology”

Using anabolic androgenic steroids can cause serious, lasting health problems in many parts of the body.

research Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline

855 citations, June 2009 in “The Journal of Clinical Endocrinology & Metabolism”

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.